NCI-2024-07296

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

This Phase 1 research study is highly specific and is for patients with advanced or metastatic solid tumors (cancer that has spread or come back) that have a specific defect: a mutation or change in the SMARCA4 gene. This specific gene change is found in about 10% of non-small cell lung cancers and 5% of all cancers in general. The drug PRT7732 is an example of a new kind of medicine called a Targeted Protein Degrader. It works by exploiting a key weakness in the cancer cells. Cancer cells with a broken SMARCA4 gene become completely dependent on a similar protein called SMARCA2 to survive and grow. PRT7732 is designed to act like a molecular signal that tells the cell's natural "trash disposal" system to specifically break down and destroy the SMARCA2 protein. By taking away the SMARCA2 protein, the cancer cell can no longer survive, while healthy cells (which still have the working SMARCA4 protein) are generally left alone.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

mutation: Mutation is an alteration in the genetic material of a cell or a virus that can be inherited by its descendants

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06560645

Clinical Trial Site: Sinai

To see all available clinical trials click here.